| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gas Chromatography-Mass Spectrometry | 3 | 2024 | 82 | 2.550 |
Why?
|
| Drug Contamination | 4 | 2025 | 11 | 2.190 |
Why?
|
| Neuroblastoma | 5 | 2024 | 134 | 2.030 |
Why?
|
| Methyltransferases | 3 | 2024 | 66 | 1.860 |
Why?
|
| Limit of Detection | 4 | 2025 | 82 | 1.320 |
Why?
|
| Solvents | 2 | 2024 | 109 | 1.070 |
Why?
|
| Drosophila melanogaster | 3 | 2018 | 189 | 1.070 |
Why?
|
| Contrast Media | 2 | 2025 | 101 | 1.040 |
Why?
|
| RNA, Untranslated | 8 | 2013 | 46 | 0.980 |
Why?
|
| Apoptosis | 7 | 2023 | 1541 | 0.970 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2021 | 16 | 0.970 |
Why?
|
| Polychlorinated Biphenyls | 2 | 2025 | 46 | 0.950 |
Why?
|
| RNA | 4 | 2023 | 266 | 0.950 |
Why?
|
| Gadolinium | 1 | 2025 | 30 | 0.940 |
Why?
|
| Chromatin | 6 | 2018 | 179 | 0.930 |
Why?
|
| Doxorubicin | 1 | 2025 | 95 | 0.900 |
Why?
|
| Neural Crest | 1 | 2024 | 27 | 0.880 |
Why?
|
| Dimethylamines | 1 | 2024 | 1 | 0.880 |
Why?
|
| Dimethylformamide | 1 | 2024 | 8 | 0.880 |
Why?
|
| o-Phthalaldehyde | 1 | 2024 | 4 | 0.860 |
Why?
|
| Ethylenediamines | 1 | 2024 | 8 | 0.860 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2021 | 40 | 0.850 |
Why?
|
| Environmental Pollutants | 2 | 2025 | 198 | 0.820 |
Why?
|
| Metabolic Diseases | 1 | 2023 | 38 | 0.810 |
Why?
|
| Fatty Liver | 1 | 2023 | 71 | 0.790 |
Why?
|
| Radiopharmaceuticals | 2 | 2021 | 62 | 0.790 |
Why?
|
| Furin | 1 | 2022 | 6 | 0.750 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2022 | 21 | 0.740 |
Why?
|
| Antibodies, Neutralizing | 2 | 2022 | 118 | 0.740 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2025 | 577 | 0.730 |
Why?
|
| Humans | 45 | 2025 | 42163 | 0.730 |
Why?
|
| Cell Differentiation | 1 | 2024 | 633 | 0.700 |
Why?
|
| Guanine | 1 | 2021 | 45 | 0.700 |
Why?
|
| Cell Line, Tumor | 12 | 2025 | 2598 | 0.700 |
Why?
|
| DNA Damage | 3 | 2020 | 358 | 0.690 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 211 | 0.690 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 295 | 0.660 |
Why?
|
| Antineoplastic Agents | 2 | 2025 | 979 | 0.660 |
Why?
|
| Ovarian Neoplasms | 2 | 2025 | 406 | 0.650 |
Why?
|
| Fluorine Radioisotopes | 1 | 2019 | 12 | 0.640 |
Why?
|
| Gamma Rays | 1 | 2019 | 27 | 0.630 |
Why?
|
| Genomic Imprinting | 5 | 2013 | 35 | 0.630 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2024 | 933 | 0.620 |
Why?
|
| Chromosome Aberrations | 1 | 2019 | 61 | 0.610 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2018 | 74 | 0.600 |
Why?
|
| Histones | 6 | 2021 | 194 | 0.600 |
Why?
|
| Drosophila Proteins | 2 | 2018 | 183 | 0.590 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2022 | 744 | 0.570 |
Why?
|
| SOX9 Transcription Factor | 1 | 2018 | 10 | 0.570 |
Why?
|
| Fibroblasts | 1 | 2019 | 278 | 0.560 |
Why?
|
| Immunoprecipitation | 1 | 2018 | 128 | 0.550 |
Why?
|
| Epigenesis, Genetic | 5 | 2021 | 274 | 0.540 |
Why?
|
| Benzoxazoles | 1 | 2017 | 10 | 0.540 |
Why?
|
| Reproducibility of Results | 6 | 2025 | 1058 | 0.530 |
Why?
|
| Triazoles | 1 | 2017 | 100 | 0.500 |
Why?
|
| RNA, Viral | 3 | 2023 | 317 | 0.500 |
Why?
|
| Gene Expression Regulation | 4 | 2018 | 1066 | 0.500 |
Why?
|
| Animals | 22 | 2025 | 16695 | 0.470 |
Why?
|
| Transcription, Genetic | 5 | 2018 | 599 | 0.460 |
Why?
|
| Linear Models | 3 | 2025 | 311 | 0.450 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2025 | 230 | 0.450 |
Why?
|
| Fas Ligand Protein | 2 | 2025 | 17 | 0.450 |
Why?
|
| Cell Proliferation | 4 | 2025 | 1420 | 0.430 |
Why?
|
| MicroRNAs | 2 | 2017 | 501 | 0.430 |
Why?
|
| Immunotherapy | 3 | 2025 | 137 | 0.400 |
Why?
|
| Benzimidazoles | 2 | 2025 | 41 | 0.380 |
Why?
|
| Cytochrome P-450 CYP2D6 | 2 | 2022 | 19 | 0.380 |
Why?
|
| Mice | 15 | 2025 | 6490 | 0.370 |
Why?
|
| Hepacivirus | 2 | 2008 | 73 | 0.350 |
Why?
|
| Cephalometry | 1 | 2011 | 5 | 0.350 |
Why?
|
| Gene Silencing | 6 | 2013 | 154 | 0.350 |
Why?
|
| Skull | 1 | 2011 | 27 | 0.350 |
Why?
|
| Face | 1 | 2011 | 41 | 0.340 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2021 | 39 | 0.340 |
Why?
|
| Cell Line | 6 | 2019 | 1416 | 0.340 |
Why?
|
| Neoplasms | 4 | 2025 | 1341 | 0.330 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 170 | 0.320 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 301 | 0.310 |
Why?
|
| Gene Expression Profiling | 4 | 2023 | 683 | 0.310 |
Why?
|
| Chromatin Assembly and Disassembly | 3 | 2018 | 44 | 0.300 |
Why?
|
| Glycolysis | 2 | 2019 | 71 | 0.300 |
Why?
|
| Protein Biosynthesis | 2 | 2008 | 136 | 0.290 |
Why?
|
| Ribonucleoproteins | 1 | 2008 | 31 | 0.290 |
Why?
|
| Autoantigens | 1 | 2008 | 85 | 0.280 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 290 | 0.280 |
Why?
|
| Karyopherins | 2 | 2025 | 7 | 0.280 |
Why?
|
| Algorithms | 1 | 2011 | 508 | 0.280 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2025 | 66 | 0.270 |
Why?
|
| Antiviral Agents | 2 | 2025 | 189 | 0.260 |
Why?
|
| Slovakia | 2 | 2025 | 9 | 0.250 |
Why?
|
| Epitopes | 2 | 2023 | 155 | 0.240 |
Why?
|
| RNA, Antisense | 3 | 2011 | 18 | 0.240 |
Why?
|
| Fibrinolysin | 1 | 2025 | 9 | 0.240 |
Why?
|
| Tranexamic Acid | 1 | 2025 | 3 | 0.230 |
Why?
|
| Antifibrinolytic Agents | 1 | 2025 | 4 | 0.230 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2025 | 52 | 0.230 |
Why?
|
| Photochemotherapy | 1 | 2025 | 42 | 0.230 |
Why?
|
| Acetates | 1 | 2025 | 29 | 0.230 |
Why?
|
| Maternal Exposure | 1 | 2025 | 56 | 0.230 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2025 | 147 | 0.230 |
Why?
|
| Piperidines | 1 | 2025 | 80 | 0.220 |
Why?
|
| Quinolines | 1 | 2025 | 76 | 0.220 |
Why?
|
| Adenosine | 1 | 2024 | 62 | 0.220 |
Why?
|
| T-Lymphocytes | 2 | 2025 | 378 | 0.220 |
Why?
|
| Benzoates | 1 | 2024 | 17 | 0.220 |
Why?
|
| Adenine | 1 | 2024 | 48 | 0.210 |
Why?
|
| Molecular Dynamics Simulation | 2 | 2025 | 183 | 0.210 |
Why?
|
| Polymers | 1 | 2025 | 151 | 0.210 |
Why?
|
| Amino Acid Sequence | 2 | 2022 | 1188 | 0.210 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2022 | 206 | 0.210 |
Why?
|
| Indoles | 1 | 2025 | 178 | 0.210 |
Why?
|
| Benzamides | 1 | 2024 | 78 | 0.210 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2025 | 188 | 0.210 |
Why?
|
| Telomere | 1 | 2024 | 59 | 0.210 |
Why?
|
| Pharmaceutical Preparations | 1 | 2024 | 93 | 0.200 |
Why?
|
| Antibodies | 1 | 2023 | 140 | 0.200 |
Why?
|
| Cricetulus | 2 | 2020 | 82 | 0.200 |
Why?
|
| Methylation | 1 | 2023 | 118 | 0.200 |
Why?
|
| District of Columbia | 1 | 2022 | 73 | 0.190 |
Why?
|
| Gene Expression | 1 | 2025 | 692 | 0.190 |
Why?
|
| Dyslipidemias | 1 | 2022 | 48 | 0.190 |
Why?
|
| Cell Survival | 1 | 2025 | 934 | 0.180 |
Why?
|
| Female | 12 | 2025 | 24018 | 0.180 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2021 | 10 | 0.180 |
Why?
|
| Virus Internalization | 1 | 2022 | 36 | 0.180 |
Why?
|
| Apolipoproteins E | 1 | 2022 | 137 | 0.180 |
Why?
|
| Green Chemistry Technology | 3 | 2025 | 6 | 0.180 |
Why?
|
| Immune Evasion | 1 | 2021 | 17 | 0.170 |
Why?
|
| Insulin-Secreting Cells | 1 | 2021 | 28 | 0.170 |
Why?
|
| rho-Associated Kinases | 1 | 2021 | 35 | 0.170 |
Why?
|
| Pilot Projects | 1 | 2023 | 733 | 0.170 |
Why?
|
| Antibodies, Bispecific | 1 | 2020 | 5 | 0.170 |
Why?
|
| Genomics | 1 | 2022 | 289 | 0.170 |
Why?
|
| Sequence Analysis, RNA | 2 | 2018 | 114 | 0.170 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2018 | 30 | 0.160 |
Why?
|
| Host-Pathogen Interactions | 1 | 2022 | 203 | 0.160 |
Why?
|
| Nerve Tissue Proteins | 1 | 2022 | 382 | 0.160 |
Why?
|
| Mitochondria | 3 | 2020 | 516 | 0.160 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2013 | 303 | 0.160 |
Why?
|
| Chromatids | 1 | 2019 | 2 | 0.160 |
Why?
|
| Environmental Exposure | 1 | 2022 | 247 | 0.160 |
Why?
|
| Carbocyanines | 1 | 2019 | 14 | 0.160 |
Why?
|
| Karyotyping | 1 | 2019 | 44 | 0.160 |
Why?
|
| Aneuploidy | 1 | 2019 | 24 | 0.160 |
Why?
|
| Nanoparticles | 1 | 2025 | 449 | 0.160 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2020 | 90 | 0.160 |
Why?
|
| Chromosomes | 1 | 2019 | 44 | 0.160 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2019 | 17 | 0.160 |
Why?
|
| Body Weight | 1 | 2021 | 428 | 0.150 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2019 | 89 | 0.150 |
Why?
|
| Aerobiosis | 1 | 2019 | 15 | 0.150 |
Why?
|
| Male | 9 | 2025 | 22779 | 0.150 |
Why?
|
| Whole Body Imaging | 1 | 2019 | 25 | 0.150 |
Why?
|
| Comet Assay | 1 | 2019 | 77 | 0.150 |
Why?
|
| Gallbladder Neoplasms | 1 | 2018 | 3 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 209 | 0.150 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2025 | 458 | 0.150 |
Why?
|
| Mitosis | 1 | 2019 | 112 | 0.150 |
Why?
|
| Forkhead Transcription Factors | 1 | 2019 | 75 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 233 | 0.140 |
Why?
|
| Ubiquitination | 1 | 2018 | 60 | 0.140 |
Why?
|
| Phosphorylation | 2 | 2019 | 973 | 0.140 |
Why?
|
| DNA Methylation | 2 | 2012 | 393 | 0.140 |
Why?
|
| DNA Repair | 1 | 2019 | 196 | 0.140 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2018 | 31 | 0.140 |
Why?
|
| Workflow | 1 | 2018 | 23 | 0.140 |
Why?
|
| Cell Cycle | 1 | 2019 | 348 | 0.140 |
Why?
|
| Reactive Oxygen Species | 2 | 2019 | 518 | 0.140 |
Why?
|
| S Phase | 1 | 2018 | 37 | 0.140 |
Why?
|
| Child, Preschool | 1 | 2022 | 1516 | 0.140 |
Why?
|
| Organogenesis | 1 | 2017 | 16 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 284 | 0.130 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2018 | 55 | 0.130 |
Why?
|
| Eye | 1 | 2018 | 80 | 0.130 |
Why?
|
| Caspases | 1 | 2017 | 148 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2018 | 222 | 0.130 |
Why?
|
| Lung | 1 | 2019 | 484 | 0.130 |
Why?
|
| Evolution, Molecular | 2 | 2025 | 299 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 3 | 2018 | 534 | 0.120 |
Why?
|
| KCNQ1 Potassium Channel | 2 | 2012 | 2 | 0.120 |
Why?
|
| Antioxidants | 1 | 2019 | 439 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2021 | 339 | 0.120 |
Why?
|
| Signal Transduction | 3 | 2025 | 2111 | 0.120 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 44 | 0.120 |
Why?
|
| Neuropeptides | 1 | 2015 | 63 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 557 | 0.110 |
Why?
|
| Protein Conformation | 2 | 2021 | 420 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 214 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 479 | 0.100 |
Why?
|
| Child | 1 | 2022 | 3381 | 0.100 |
Why?
|
| Models, Biological | 1 | 2017 | 711 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 255 | 0.100 |
Why?
|
| Protein Binding | 3 | 2025 | 1076 | 0.100 |
Why?
|
| Conserved Sequence | 2 | 2010 | 121 | 0.100 |
Why?
|
| DNA | 1 | 2015 | 594 | 0.090 |
Why?
|
| United States | 1 | 2022 | 5072 | 0.090 |
Why?
|
| Cell Nucleolus | 2 | 2008 | 11 | 0.090 |
Why?
|
| Radiography | 1 | 2011 | 72 | 0.090 |
Why?
|
| Head | 1 | 2011 | 28 | 0.090 |
Why?
|
| Mice, Inbred NOD | 2 | 2021 | 50 | 0.080 |
Why?
|
| Postpartum Hemorrhage | 1 | 2010 | 19 | 0.080 |
Why?
|
| Radiation Dosage | 2 | 2021 | 37 | 0.080 |
Why?
|
| DNA, Intergenic | 1 | 2010 | 11 | 0.080 |
Why?
|
| Young Adult | 1 | 2021 | 4936 | 0.080 |
Why?
|
| Adult | 3 | 2025 | 13458 | 0.080 |
Why?
|
| Mice, SCID | 2 | 2021 | 158 | 0.080 |
Why?
|
| Introns | 1 | 2010 | 80 | 0.080 |
Why?
|
| Brain | 1 | 2018 | 1452 | 0.080 |
Why?
|
| High-Throughput Screening Assays | 1 | 2010 | 72 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2011 | 336 | 0.080 |
Why?
|
| Mammals | 1 | 2010 | 109 | 0.080 |
Why?
|
| Middle Aged | 2 | 2021 | 11819 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2008 | 1559 | 0.070 |
Why?
|
| Ribosomes | 1 | 2008 | 34 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 1804 | 0.070 |
Why?
|
| DNA, Catalytic | 1 | 2008 | 2 | 0.070 |
Why?
|
| Binding Sites | 2 | 2021 | 670 | 0.070 |
Why?
|
| 3' Untranslated Regions | 1 | 2008 | 81 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 508 | 0.070 |
Why?
|
| Pregnancy | 3 | 2025 | 1737 | 0.070 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2008 | 300 | 0.070 |
Why?
|
| India | 2 | 2021 | 105 | 0.070 |
Why?
|
| Mutation | 3 | 2021 | 1169 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2021 | 1617 | 0.060 |
Why?
|
| Tablets | 1 | 2025 | 11 | 0.060 |
Why?
|
| Fetal Blood | 1 | 2025 | 48 | 0.060 |
Why?
|
| Cyclopropanes | 1 | 2025 | 42 | 0.060 |
Why?
|
| Hydrogen Bonding | 1 | 2025 | 143 | 0.060 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2025 | 93 | 0.060 |
Why?
|
| Drug Stability | 1 | 2025 | 127 | 0.060 |
Why?
|
| Sulfides | 1 | 2025 | 77 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2008 | 548 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2025 | 173 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2008 | 1265 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2024 | 60 | 0.050 |
Why?
|
| Pakistan | 1 | 2022 | 20 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2025 | 960 | 0.050 |
Why?
|
| PPAR alpha | 1 | 2022 | 43 | 0.050 |
Why?
|
| Triglycerides | 1 | 2022 | 146 | 0.050 |
Why?
|
| CpG Islands | 2 | 2012 | 107 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2021 | 76 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2021 | 84 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2021 | 13 | 0.040 |
Why?
|
| Cell Fractionation | 1 | 2020 | 30 | 0.040 |
Why?
|
| Cholesterol | 1 | 2022 | 230 | 0.040 |
Why?
|
| Lipids | 1 | 2022 | 256 | 0.040 |
Why?
|
| Staphylococcal Protein A | 1 | 2020 | 1 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2020 | 41 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2020 | 154 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 386 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 188 | 0.040 |
Why?
|
| CHO Cells | 1 | 2020 | 123 | 0.040 |
Why?
|
| Kinetics | 1 | 2021 | 698 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2020 | 230 | 0.040 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) | 1 | 2019 | 1 | 0.040 |
Why?
|
| Hexokinase | 1 | 2019 | 10 | 0.040 |
Why?
|
| Micronucleus Tests | 1 | 2019 | 16 | 0.040 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2019 | 5 | 0.040 |
Why?
|
| Pyruvate Dehydrogenase (Lipoamide)-Phosphatase | 1 | 2019 | 2 | 0.040 |
Why?
|
| 3T3 Cells | 1 | 2019 | 61 | 0.040 |
Why?
|
| Pyruvic Acid | 1 | 2019 | 21 | 0.040 |
Why?
|
| RNA Polymerase II | 2 | 2009 | 31 | 0.040 |
Why?
|
| Heme | 1 | 2019 | 72 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2020 | 383 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2019 | 70 | 0.040 |
Why?
|
| Potassium Channels, Voltage-Gated | 2 | 2008 | 13 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 81 | 0.040 |
Why?
|
| Y-Box-Binding Protein 1 | 1 | 2018 | 1 | 0.040 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein K | 1 | 2018 | 2 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 534 | 0.040 |
Why?
|
| RNA Interference | 1 | 2019 | 246 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2019 | 110 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 233 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2019 | 89 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2018 | 506 | 0.030 |
Why?
|
| Hela Cells | 1 | 2018 | 370 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2019 | 448 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 201 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2018 | 403 | 0.030 |
Why?
|
| Time Factors | 2 | 2012 | 1848 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2019 | 436 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 686 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 452 | 0.030 |
Why?
|
| Base Sequence | 2 | 2008 | 997 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 1010 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 850 | 0.030 |
Why?
|
| Cell Movement | 1 | 2019 | 640 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 129 | 0.030 |
Why?
|
| Neurogenesis | 1 | 2014 | 64 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 289 | 0.030 |
Why?
|
| Crosses, Genetic | 1 | 2012 | 48 | 0.020 |
Why?
|
| Heterochromatin | 1 | 2012 | 19 | 0.020 |
Why?
|
| Homozygote | 1 | 2012 | 77 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2014 | 267 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 661 | 0.020 |
Why?
|
| Nucleosomes | 1 | 2011 | 31 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2011 | 92 | 0.020 |
Why?
|
| Lysine | 1 | 2011 | 120 | 0.020 |
Why?
|
| Embryonic Development | 1 | 2011 | 83 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2011 | 158 | 0.020 |
Why?
|
| Placenta | 1 | 2011 | 113 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2011 | 190 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2011 | 184 | 0.020 |
Why?
|
| Testis | 1 | 2011 | 203 | 0.020 |
Why?
|
| Spermatogenesis | 1 | 2011 | 160 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 236 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 658 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 860 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 427 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 352 | 0.020 |
Why?
|
| Histocompatibility Antigens | 1 | 2008 | 12 | 0.020 |
Why?
|
| RNA Stability | 1 | 2008 | 28 | 0.020 |
Why?
|
| Enterovirus B, Human | 1 | 2008 | 2 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2008 | 149 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2008 | 148 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 2008 | 156 | 0.020 |
Why?
|
| Plasmids | 1 | 2008 | 247 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2008 | 196 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2010 | 1574 | 0.020 |
Why?
|
| Virus Replication | 1 | 2008 | 318 | 0.020 |
Why?
|
| Risk Factors | 1 | 2010 | 3942 | 0.010 |
Why?
|